

Prevalence and clinical presentation of cutaneous herpesvirus infections in the inpatient setting: a cross-sectional, single-institutional study

Kayla Babbush BS, Anthony K. Guzman MD, D. Yitzchak Goldstein MD, Yevgeniy Balagula MD

Division of Dermatology, Department of Medicine
Albert Einstein College of Medicine/ Montefiore Medical Center

Montefiore

Introduction

- Cutaneous human herpesvirus (HHV) infections have a wide spectrum of cutaneous manifestations.
- Lesion morphology and distribution may vary in primary versus reactivation stage of disease and is impacted by the patient's immune status.
- Reactivation triggers include stress, fever, UV exposure, and immunosuppression.
- These infections may complicate hospital stays, increase morbidity, and present a diagnostic challenge.
- The primary objective of this cross-sectional analysis was to characterize the prevalence, clinical presentation and co-morbidities of inpatient herpesvirus infections.

Methods

- Retrospective electronic medical record review at an academic medical center from August 2018 to August 2019.
- All HSV/VZV polymerase chain reaction skin tests performed during this interval were included.
- Primary versus recurrent infection status, primary lesion morphology and distribution were recorded.

Results

- A total of 117 patients were identified and included.
- 57 patients had HSV-1, 38 had HSV-2, and 23 had VZV.

Table 1. Type of outbreak.

| HSV-1 | HSV-2 | VZV |
|--------------------------|------------------|----------------------------|
| Primary | Primary | Primary |
| 4 (7%) | 1 (3%) | 3 (13%) |
| Recurrent | Recurrent | Herpes zoster |
| 44 (77%) | 30 (79%) | 10 (43%) |
| Eczema herpeticum | Neonatal | Disseminated zoster |
| 4 (7%) | 2 (5%) | 10 (43%) |
| Herpetic syphilis | Unknown | |
| 1 (2%) | 5 (13%) | |
| Unknown | | |
| 4 (7%) | | |

Results (continued)

Table 2. Reason for admission and consult.

| | HSV-1 | HSV-2 | VZV | Total |
|---------------------------------------|----------|----------|----------|----------|
| Primary reason for admission | | | | |
| | 13 (23%) | 4 (11%) | 15 (65%) | 32 (27%) |
| | 44 (77%) | 34 (89%) | 8 (35%) | 86 (73%) |
| Reason for dermatology consult | | | | |
| | 6 (11%) | 3 (8%) | 8 (35%) | 17 (14%) |
| | 6 (11%) | 7 (18%) | 3 (13%) | 16 (14%) |
| | 5 (9%) | 4 (11%) | 4 (17%) | 13 (11%) |
| | 10 (18%) | 8 (21%) | 2 (9%) | 20 (17%) |
| | 30 (53%) | 16 (42%) | 6 (26%) | 52 (44%) |

Table 3. Location of lesions.

| | HSV-1 | HSV-2 | VZV | Total |
|------------------------|----------|----------|----------|----------|
| Head/neck | 49 (86%) | 6 (16%) | 8 (35%) | 63 (53%) |
| Upper extremity | 1 (2%) | 0 (0%) | 11 (48%) | 12 (10%) |
| Lower extremity | 1 (2%) | 3 (8%) | 10 (43%) | 14 (12%) |
| Trunk | 1 (2%) | 7 (18%) | 15 (65%) | 23 (19%) |
| Groin | 5 (9%) | 14 (37%) | 1 (4%) | 20 (17%) |
| Buttocks | 2 (4%) | 18 (47%) | 7 (30%) | 27 (23%) |
| Acral | 2 (4%) | 1 (3%) | 1 (4%) | 4 (3%) |

Table 4. Patient risk factors.

| | HSV-1 | HSV-2 | VZV | Total |
|---|----------|----------|---------|----------|
| Immunosuppressive medications | 26 (46%) | 16 (42%) | 9 (39%) | 51 (43%) |
| Hematopoietic stem cell transplant | 4 (7%) | 1 (3%) | 2 (9%) | 7 (6%) |
| Solid organ transplant | 5 (9%) | 1 (3%) | 0 (0%) | 6 (5%) |
| Presence of GVHD | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Pregnancy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Connective tissue disease | 0 (0%) | 1 (3%) | 2 (9%) | 3 (3%) |
| HIV/AIDS | 3 (5%) | 7 (18%) | 1 (4%) | 11 (9%) |
| Inherited immunodeficiency | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Hematologic malignancy | 14 (25%) | 6 (16%) | 6 (26%) | 26 (22%) |
| Solid malignancy | 3 (5%) | 5 (13%) | 3 (13%) | 11 (9%) |
| Radiation | 0 (0%) | 1 (3%) | 1 (4%) | 2 (2%) |
| Diabetes mellitus | 9 (16%) | 12 (21%) | 5 (22%) | 26 (22%) |

Figures A-I. Patient photos representing various lesion morphologies and location of disease involvement.



Results (continued)

Table 5. Characterization of lesions.

| HSV-1 | |
|---|------------|
| Ulceration/erosion | 22 (39.3%) |
| Crusted ulceration/erosion | 17 (30.4%) |
| Crusted erythematous papules | 7 (12.5%) |
| Crusted vesicles on an erythematous base | 3 (5.4%) |
| Crusted vesicopustules | 1 (1.8%) |
| Ulcerated nodule | 1 (1.8%) |
| Erythematous papules | 1 (1.8%) |
| Erosive hemorrhagic stomatitis | 1 (1.8%) |
| Crusted erosion | 1 (1.8%) |
| Punched out erosion | 1 (1.8%) |
| Crusted plaque | 1 (1.8%) |
| HSV-2 | |
| Crusted vesicles on an erythematous base | 14 (35.9%) |
| Ulcer | 10 (26.5%) |
| Ulceration/erosions | 8 (20.5%) |
| Erosions | 4 (10.3%) |
| Vesicopustules on an erythematous base | 1 (2.6%) |
| Large plaque studded with vesicles | 1 (2.6%) |
| Erythematous macules | 1 (2.6%) |
| VZV | |
| Dermatomal papules, vesicles, or pustules with erythematous base | 8 (34.8%) |
| Disseminated vesicles, pustules, and/or crusted papules with erythematous base | 7 (30.4%) |
| Scalloped crusted erosions or ulcers | 4 (17.4%) |
| Plaque studded with vesicles, bullae, and/or scalloped erosions | 3 (13.0%) |
| Hypopigmented lesions | 1 (4.3%) |

Conclusions

- A wide spectrum of clinical presentations and lesion morphologies may be seen in the setting of HHV infections in the inpatient setting.
- A significant proportion of infections (30.8%) were identified as an incidental findings by dermatology consult services
- A significant proportion of patients (55%) had underlying immunosuppressive state.
- Increased vigilance and low threshold for testing in this patient population may improve diagnostic accuracy.

References

Guida B. Herpesviruses: latency and reactivation - viral strategies and host response. *J Oral Microbiol*. 2013;5:10.3402/jom.v5i4053400.2276.
 In: Arvin A, Campadello-Fumè G, Mocarski E, et al., eds. *Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis*. Cambridge: Cambridge University Press; Copyright (c) Cambridge University Press 2007; 2007.
 Vilibic-Cavlek T, Kolarik B, Bogdanic M, Tabain I, Beader N. Herpes Group Viruses: a Seroprevalence Study in Hemodialysis Patients. *Acta Clin Croat*. 2017;56(2):265-261.
 Wurzer P, Gullory A, Parviz D, et al. Human herpes viruses in burn patients: A systematic review. *Burns*. 2017;43(1):25-33.